Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03079531 · ClinicalTrials.gov registry record · Phase 1
Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea
A Phase 1 study, sponsored by Anne Chang.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03079531 is a Phase 1 study that has completed, run by Anne Chang. The registered enrollment target is 24 participants.
The verdict
NCT03079531, a Phase 1 study, has completed, sponsored by Anne Chang.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea.
Interventions
- DRUG Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-06-21 |
| Est. Completion | 2019-01-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03079531
The ClinicalTrials.gov registry entry for NCT03079531 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anne Chang, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Secukinumab is the first listed.
NCT03079531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03079531 about?
NCT03079531 is a clinical study titled "Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea". This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea.
What is the current status of trial NCT03079531?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-06-21. Estimated completion is 2019-01-25.
What interventions are being tested in trial NCT03079531?
The interventions under investigation include: Secukinumab (DRUG).
Who is sponsoring clinical trial NCT03079531?
This trial is sponsored by Anne Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.